Skip Navigation

European Heart Journal 1999 20(20):1452-1458; doi:10.1053/euhj.1999.1659
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Van de Werf, F.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van de Werf, F.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review

The ideal fibrinolytic: can drug design improve clinical results?

F.J. Van de Werff1

Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium

revised April 19, 1999; accepted April 21, 1999

Key Words: Fibrinolytics, acute myocardial infarction, thrombolytic therapy

f1 Correspondence : Frans J. Van de Werf, MD, Chairman, Department of Cardiology, Gasthuisberg University Hospital, Herestraat 49, B-3000 Leuven, Belgium.

References

  1. N Engl J Med. 1993;329:1615–1622[Abstract/Free Full Text]
  2. Bode C, Smalling RW, Gunther B. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891–898[Abstract/Free Full Text]
  3. N Engl J Med. 1993;329:673–682[Abstract/Free Full Text]
  4. N Engl J Med. 1997;337:1118–1123[Abstract/Free Full Text]
  5. N Engl J Med. 1997;337:1124–1130[Abstract/Free Full Text]
  6. Lancet. 1995;346:329–336[CrossRef][ISI][Medline]
  7. Modi NB, Eppler S, Breed J, Cannon CP, Graunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost. 1998;79:134–139[ISI][Medline]
  8. Keyt B, Paoni NF, Refino CJ. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91:3670–3674[Abstract/Free Full Text]
  9. DeMarco E, Rebuzzi AG, Quaranta G. Lack of procoagulant effect after TNK-plasminogen activator in patients with acute myocardial infarction. Eur Heart J. 1998;19:5
  10. Benedict CR, Refino CJ, Keyt BA. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 1995;92:3032–3040[Abstract/Free Full Text]
  11. Collen D, Stassen J-M, Yasuda T. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1 resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost. 1994;72:98–104[ISI][Medline]
  12. Tanswell P, Tebbe U, Neuhaus K-L, Glasle-Schwarz L, Wojcik J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol. 1992;19:1071–1075[Abstract]
  13. Cannon CP, McCabe CH, Gibson CM. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-Ranging Trial. Circulation. 1997;95:351–356[Abstract/Free Full Text]
  14. Cannon CP, Gibson CM, McCabe CH. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B trial. Circulation. 1998;98:2805–2814[Abstract/Free Full Text]
  15. Gibson M, Cannon CP, McCabe CH, Van de Werf FJ, Braunwald E. A randomized prospective comparison of TPA with TNK using the TIMI frame count: results of TIMI 10B. Circulation. 1997;26:I-330–I-331
  16. Gugliano RP, Cannon CP, McCabe CH, Van de Werf FJ, Braunwald E. Lower dose heparin with thrombolysis is associated with lower rates of intracranial haemorrhage: results from TIMI 10B and ASSENTI. Circulation. 1997;96:I-535
  17. Garabedian HD, Svizzero TA, Guerrero JL. A new dosing strategy for TNK variant of tissue plasminogen activator eliminates heparin and reduces bleeding without loss of thrombolytic efficacy. Circulation. 1995;92:I-740
  18. Lerakis S, Stouffer GA, Runge MS. New thrombolytics. What is under development. BioDrugs. 1997;4:24–32
  19. Liao WC, Beierle FA, Stouffer BC. Single-bolus regimen of lanoteplase (nPA) in acute myocardial infarction: pharmacokinetic evaluation from InTime-1 study. Circulation. 1997;96:260–261[Abstract/Free Full Text]
  20. Ogata N, Ogata Y, Hokamaki J, Araki H, Morikami Y, Numata Y. Serial changes of PAI-1 activity in thrombolytic therapy for acute myocardial infarction. Comparison between thrombolytic therapies with lanoteplase and alteplase. Circulation. 1996;94:I-89
  21. den Heijer P, Vermeer F, Ambrosioni E. Evaluation of a weight-adjusted single bolus plasminogen activator in patients with myocardial infarction. Circulation. 1998;98:2117–2125[Abstract/Free Full Text]
  22. Lijnen HR, Van Hoef B, Matsuo O, Collen D. On the molecular interactions between plasminogen-staphylokinase, {alpha}2-antiplasmin and fibrin. Biochim Biophys Acta. 1992;1118:144–148[CrossRef][Medline]
  23. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation. 1993;87:1850–1853[Abstract/Free Full Text]
  24. Vanderschueren S, Barrios L, Kerdsinchai P. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation. 1995;92:2044–2049[Abstract/Free Full Text]
  25. Vanderschueren S, Collen D, Van de Werf F. A pilot study on bolus administration of recombinant staphylokinase for coronary artery thombolysis. Thromb Haemost. 1996;76:541–544[ISI][Medline]
  26. Vanderschueren S, Dens J, Kerdsinchai P. A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J. 1997;134:213–219[CrossRef][ISI][Medline]
  27. Okada K, Lijnen HR, Moreau H, Vanderschueren S, Collen D. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator. Thromb Haemost. 1996;76:857–859[ISI][Medline]
  28. Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost. 1994;72:297–301[ISI][Medline]
  29. Collen D, Vanderschueren S, Van de Werf F. Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Haemostasis. 1996;26:294–300
  30. Stringer KA. Biochemical and pharmacologic comparison of thrombolytic agents. Pharmacotherapy. 1996;16:119S–126S[Medline]
  31. Lancet. 1989;i:863–868
  32. Tebbe U, Michels R, Adgey J. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol. 1998;31:487–493[Abstract/Free Full Text]
  33. Spiecker M, Meyer J. Prourokinase for infarct therapy. Herz. 1994;19:326–335[ISI][Medline]
  34. Bär FW, Meyer J, Vermeer F. Comparison of saruplase and alteplase in acute myocardial infarction. Am J Cardiol. 1997;79:727–732[CrossRef][ISI][Medline]
  35. Bär FW. The bolus versus infusion in rescupase (saruplase) development (BIRD). Circulation. 1998;89:I-505
  36. Gardell SJ, Ramjit DR, Stabilito II. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation. 1991;84:244–253[Abstract/Free Full Text]
  37. Gulba DC, Bode C, Runge MS, Huber K. Thrombolytic agents—an overview. Ann Hematol. 1996;73:S9–S27
  38. Mellott MJ, Stabilito H, Holahan MA. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb. 1992;12:212–221[Abstract/Free Full Text]
  39. Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation. 1995;91:1540–1544[Abstract/Free Full Text]
  40. Witt W, Kirchhoff D, Woy P, Zierz R, Bhargava AS. Antibody formation and effects on endogenous fibrinolysis after repeated administration of DSPA alpha 1 in rats. Fibrinolysis. 1994;8:66
  41. Antman EM, Giugliano RP, Gibson MC. Abciximab facilitates the rate and extent of thrombolysis: results of TIMI 14 trail. Circulation. 1999;99:2720–2732[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CLIN APPL THROMB HEMOSTHome page
T. W. Stief
In vitro Simulation of Therapeutic Thrombolysis With Microtiter Plate Clot-Lysis Assay
Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 21 - 32.
[Abstract] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
T. W. Stief, R. Buinder, A. Richter, B. Maisch, H. Renz, and J. Fareed
In vitro Simulation of Therapeutic Plasmatic Fibrinolysis
Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 211 - 220.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
F. Van de Werf
In TIME-II: more than a study on lanoteplase
Eur. Heart J., December 2, 2000; 21(24): 1996 - 1997.
[PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Van de Werf, F.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van de Werf, F.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?